Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$295.22 -0.7%	$281.33	$253.30 ▼ $346.85	$158.74B	0.51	2.82 million shs	2.19 million shs
AZN AstraZeneca	$74.42 -0.8%	$69.81	$61.24 ▼ $87.68	$230.80B	0.38	5.20 million shs	3.13 million shs
NVAX Novavax	$6.94 -2.9%	$6.71	$5.01 ▼ $17.81	$1.12B	2.81	6.53 million shs	5.16 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	-0.70%	+1.68%	+12.56%	-5.89%	-1.95%
AZN AstraZeneca	-0.77%	+2.11%	+12.37%	-4.10%	-7.06%
NVAX Novavax	-2.94%	-6.85%	+16.44%	-13.14%	-56.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.4609 of 5 stars	2.2	4.0	3.3	3.9	3.6	2.5	0.6
AZN AstraZeneca	2.8601 of 5 stars	2.6	5.0	1.7	0.0	2.8	0.0	1.3
NVAX Novavax	3.8658 of 5 stars	3.3	2.0	0.0	4.7	2.7	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.38	Hold	$309.22	4.74% Upside
AZN AstraZeneca	3.13	Buy	$85.00	14.22% Upside
NVAX Novavax	2.50	Moderate Buy	$19.20	176.66% Upside

Current Analyst Ratings Breakdown

Latest AMGN, NVAX, and AZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/2/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$319.00 ➝ $315.00
5/2/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
5/2/2025	AMGN Amgen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$324.00 ➝ $320.00
4/22/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$305.00
4/15/2025	AZN AstraZeneca	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$75.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$34.13B	4.65	$29.58 per share	9.98	$10.93 per share	27.01
AZN AstraZeneca	$54.98B	4.20	$6.31 per share	11.79	$13.18 per share	5.65
NVAX Novavax	$1.21B	0.93	N/A	N/A	($6.04) per share	-1.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	39.10	13.80	2.63	12.24%	176.32%	11.71%	8/5/2025 (Estimated)
AZN AstraZeneca	$7.04B	$2.49	32.93	14.88	1.42	13.01%	32.23%	12.31%	7/24/2025 (Estimated)
NVAX Novavax	-$545.06M	$2.65	N/A	86.75	2.85	-32.18%	N/A	-17.05%	8/14/2025 (Estimated)

Latest AMGN, NVAX, and AZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/29/2025	Q1 2025	AZN AstraZeneca	$1.10	$1.24	+$0.14	$0.93	$13.71 billion	$13.59 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.22%	N/A	86.86%	14 Years
AZN AstraZeneca	$2.06	2.77%	N/A	82.73%	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
AZN AstraZeneca	0.65	0.93	0.74
NVAX Novavax	N/A	0.93	0.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
AZN AstraZeneca	20.35%
NVAX Novavax	53.04%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
AZN AstraZeneca	N/A
NVAX Novavax	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	25,200	537.71 million	533.50 million	Optionable
AZN AstraZeneca	83,500	3.10 billion	N/A	Optionable
NVAX Novavax	1,990	161.97 million	158.58 million	Optionable

AMGN, NVAX, and AZN Headlines

Recent News About These Companies

Analysts Conflicted on These Healthcare Names: Novavax (NVAX) and Intuitive Surgical (ISRG)

June 14 at 3:02 AM | theglobeandmail.com

Novavax: New Vaccine, Same Old Story - Still A Sell

June 13 at 11:52 AM | seekingalpha.com

Novavax, Inc. (NASDAQ:NVAX) Shares Sold by SG Americas Securities LLC

June 13 at 4:21 AM | marketbeat.com

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

June 12 at 9:16 AM | zacks.com

Novavax's COVID-flu combo vaccine shows strong immune response in trial

June 12 at 8:10 AM | msn.com

Novavax preps late-stage trial as COVID-flu combo vaccine matches rivals

June 12 at 8:10 AM | thepharmaletter.com

Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

June 11 at 10:09 PM | seekingalpha.com

Novavax’s COVID-flu combo vaccine shows strong immune response

June 11 at 10:08 PM | msn.com

Tesla, Victoria’s Secret, Novavax rise premarket; Chewy, Gitlab fall

June 11 at 5:07 PM | investing.com

Novavax posts immune data to back COVID-flu combo shot and standalone flu shot

June 11 at 5:07 PM | msn.com

Novavax (NasdaqGS:NVAX) Announces Promising Results for New Vaccine Candidates

June 11 at 5:07 PM | finance.yahoo.com

Novavax’s Covid-Flu Combo, Standalone Flu Vaccines Demonstrate Robust Immune Response In Late-Stage Trial: Retail Says It’s ‘A Very Good Sign’

June 11 at 5:07 PM | msn.com

Novavax's Experimental COVID-19-Influenza Combo Shot Shows Immune Response Among Older Adults In Phase 3 Trial

June 11 at 11:38 AM | benzinga.com

Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?

June 11 at 10:56 AM | zacks.com

Novavax Stock (NVAX) Gets a Boost from ‘Robust Immune Responses’

June 11 at 10:45 AM | tipranks.com

Novavax Reports Promising Phase 3 Vaccine Trial Results

June 11 at 7:59 AM | tipranks.com

Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study

June 11 at 7:11 AM | reuters.com

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

June 11 at 7:00 AM | prnewswire.com

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

June 10, 2025 | barrons.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.16 Million Position in Novavax, Inc. (NASDAQ:NVAX)

June 7, 2025 | marketbeat.com

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

June 6, 2025 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMGN, NVAX, and AZN Company Descriptions

Amgen NASDAQ:AMGN

$295.22 -2.07 (-0.70%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$294.75 -0.47 (-0.16%)

As of 06/13/2025 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

AstraZeneca NASDAQ:AZN

$74.42 -0.58 (-0.77%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$74.64 +0.22 (+0.30%)

As of 06/13/2025 07:16 PM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Novavax NASDAQ:NVAX

$6.94 -0.21 (-2.94%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$7.02 +0.07 (+1.08%)

As of 06/13/2025 07:59 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time